Dendritic-cell-based immunotherapy combined with low-dose cyclophosphamide in patients with malignant pleural mesothelioma.

Trial Profile

Dendritic-cell-based immunotherapy combined with low-dose cyclophosphamide in patients with malignant pleural mesothelioma.

Completed
Phase of Trial: Phase I

Latest Information Update: 24 May 2016

At a glance

  • Drugs Dendritic cell vaccine-Amphera (Primary) ; Cyclophosphamide
  • Indications Mesothelioma
  • Focus Adverse reactions
  • Most Recent Events

    • 15 Nov 2010 Planned end date changed from 10 Jan 2011 to 1 Oct 2012 as reported by ClinicalTrials.gov.
    • 15 Nov 2010 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health).
    • 09 Nov 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top